Ovid Therapeutics Inc.
OVID- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001636651
No open-market purchases or sales by Ovid Therapeutics Inc. insiders were filed in the last 90 days; 130 institutions reported holding it in 13F filings for Q2 2026, worth $395.5M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Ovid Therapeutics Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Ovid Therapeutics Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Carter Charles Ross | Chief Financial Officer | 94,375 | Jul 8, 2026 | 1 |
| Greka Anna | Director | – | Jun 17, 2026 | 1 |
| Papadopoulos Stelios | Director | 217,578 | Apr 9, 2026 | 2 |
| Friedman Bart | Director | 8,789 | Apr 9, 2026 | 2 |
| Fitzgerald Kevin Joseph | Director | 17,578 | Apr 9, 2026 | 2 |
| Levin Jeremy M | Executive Chairman | 3,735,048 | Mar 25, 2026 | 3 |
| Rona Jeffrey A | CBFO | 156,313 | Mar 2, 2026 | 1 |
| Duncan Barbara Gayle | Director | – | Mar 2, 2026 | 1 |
| Bernstein Karen | Director | – | Mar 2, 2026 | 1 |
| Alexander Margaret A. | President and CEO | 61,750 | Mar 2, 2026 | 2 |
| Takeda Pharmaceutical Co Ltd | 10% Owner | 7,000,000Indirect | Dec 9, 2025 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10% Owner | 7,000,000Indirect | Dec 9, 2025 | 1 |
| Perone Thomas Michael | General Counsel, Secretary | 28,125 | Feb 26, 2024 | 0 |
| Tardio Jason | Chief Operating Officer | 28,125 | Feb 26, 2024 | 0 |
| Poole Robert Michael | Director | – | Feb 26, 2024 | 0 |
| Rakhit Amit | President and CMO | 726,823 | Jul 16, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 (view filing) | Feb 23 | 7 daysLate | Alexander Margaret A.President and CEO | SSale | −11.7K | $1.45 | −$16.9K | −15.9%61.8K after | |
| Mar 2, 2026 (view filing) | Feb 23 | 7 daysLate | Rona Jeffrey ACBFO | SSale | −8.54K | $1.45 | −$12.4K | −8.8%88.2K after | |
| Dec 18, 2025 (view filing) | Dec 11 | 7 daysLate | Levin Jeremy MCEO | PPurchase | +153.8K | – | – | –35.5K after | Derivative3 lots |
| Feb 28, 2025 (view filing) | Feb 26 | 2 days | Alexander Margaret A.President and COO | SSale | −5.28K | $0.56 | −$2.96K | −6.7%73.4K after | |
| Feb 28, 2025 (view filing) | Feb 26 | 2 days | Rona Jeffrey ACBFO | SSale | −3.90K | $0.56 | −$2.19K | −5.4%68.0K after | |
| Jan 29, 2025 (view filing) | Jan 27 | 2 days | Alexander Margaret A.President and COO | PPurchase | +6.81K | $0.73 | +$4.97K | +24.2%34.9K after | |
| Mar 20, 2024 (view filing) | Mar 18 | 2 days | Levin Jeremy MCEO | PPurchase | +18.2K | $2.76 | +$50.4K | +0.5%3.62M after | |
| Sep 14, 2022 (view filing) | Sep 12 | 2 days | Tardio JasonChief Operating Officer | SSale | −17.3K | $2.15 | −$37.3K | −100.0%0 after | |
| Jul 16, 2021 (view filing) | Jul 14 | 2 days | Rakhit AmitPresident and CMO | SSale | −34.0K | $3.71 | −$126.2K | −4.5%726.8K after |